Head-to-head · WeighScore
Bliv vs Kova
The verdict
Bliv takes it — 66.3/100 to 44.3/100.
Bliv grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bliv is a telehealth provider selling personalised compounded GLP-1 programmes.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bliv | Kova |
|---|---|---|
| WeighScore | 66.3/100 | 44.3/100 |
| Grade | C | C |
| Scorecard rank | #187 | #498 |
| Semaglutide | $116/mo (as low as, varies by plan and eligibility, compounded) | Not disclosed |
| Tirzepatide | $199/mo (as low as, varies by plan and eligibility, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #187 · C
Strengths
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
- A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
- The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
- The only figure smaller than the advertised rate is a $29 CareCredit/Klarna instalment, which is a financing payment rather than the price of a month of medication
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #498 · C
Strengths
- Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
- Medication is included in the plan price, with no separate pharmacy charge
- States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
- Companion app tracks weight, protein and side effects, with medication schedule reminders
- You are not charged unless a provider approves treatment
Where it loses points
- At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
- The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
- Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
- Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
- No pharmacy or prescribing medical group is named anywhere on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.